1. Dezsi CA. Trimetazidine in Practice: Review of the Clinical and Experimental Evidence. American Journal of Therapeutics. 2016;23: e871–e879 DOI: 10.1097/MJT.0000000000000180
2. McCarthy CP, Mullins KV, Kerins DM. The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent. European Heart Journal. 201;2: 266– 72 doi:10.1093/ehjcvp/pvv051
3. Guarini G, Huqi A, Morrone D, et al. Trimetazidine and Other Metabolic Modifiers. European Cardiology Review. 2018;13(2): 104–111 . https://doi.org/10.15420/ecr.2018.15.2
5. MIMS. Drug Information : Trimetazidine Concise Prescribing Info. 2023. https://www.mims.com/indonesia/drug/info/trimetazidine?mtype=generic
6. BPOM :Badan Pengawas Obat dan Makanan. Pedoman Umum: Informatorium Obat Nasional Indonesia (IONI). 2015; http://pionas.pom.go.id/monografi/trimetazidin-dihidroklorida
7. Magoon R, Choudhury A, Malik V, et al. Pharmacological Update: New Drugs in Cardiac Practice: A Critical Appraisal. Annals of Cardiac Anaesthesia. 2017 ;20(1): S49–S56 doi: 10.4103/0971-9784.197798
8. Kallistratos M, Poulimenos L, Tsinivizov P, et al. Trimetazidine in the Prevention of Tissue Ischemic Conditions. Sage Journals. 2018;0: 1-8. DOI: 10.1177/0003319718780551
9. Tsioufis K, Andrikopoulus G, Monolis A. Trimetazidine and Cardioprotection : Facts and Perspective. Sage Journals. 2014;0 :1-7. DOI: 10.1177/0003319714530040
10. Marzili M, Vinereanu D, Lopaschuk G, et al. Trimetazidine in cardiovascular medicine. International Journal Of Cardiology. 2019;293:39-44. https://doi.org/10.1016/j.ijcard.2019.05.063
11. Tarkin JM, Kaski JC. Trimetazidine: is there a role beyond angina ?. European Heart Journal. 2018;(4) :67-68. doi:10.1093/ehjcvp/pvx029
12. Ferrari R, Ford I, Fox K, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. The Lancet. 2020;0 :1-9. https://doi.org/10.1016/S0140-6736(20)31790-6
13. Wu L, Luan Y, Li Y, et al. Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial. BMC Cardiovascular Disorders. 2020;20(273): 1-7. https://doi.org/10.1186/s12872-020-01557-3
14. Coats CJ, Pavlou M, Watkinson OT, et al. Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy A Randomized Clinical Trial. JAMA Cardiology.2019;4(3):230-235. doi:10.1001/jamacardio.2018.4847
15. Bovenkamp AA, Bakermans AJ, Allaart CP, et al. Trimetazidine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study.Netherlands Heart Journal.2020;0: 1-6. https://doi.org/10.1007/s12471-020-01407-z
16. Shedage A, Khana A, Gole M, et al. Comparative Steady State Cross-Over Bioequivalence Study of 35mg Trimetazidine Extended-Release Tablets. Journal of Bioequivalence & Bioavailability. 2014;6(6): 192-196. doi:10.4172/jbb.1000203